# A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

> **NCT04536792** · PHASE1 · COMPLETED · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Healthy Volunteers
- Anemia, Sickle Cell

## Interventions

- **DRUG:** AG-946
- **DRUG:** AG-946 Matched Placebo

## Key facts

- **NCT ID:** NCT04536792
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-10
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536792, "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04536792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*